<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931356</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A02487-48</org_study_id>
    <nct_id>NCT03931356</nct_id>
  </id_info>
  <brief_title>Follow-up of Pulmonary Radiotoxicity for Bronchopulmonary Cancer.</brief_title>
  <acronym>TEFRARC</acronym>
  <official_title>Follow-up of Pulmonary Toxicity by Respiratory Functional Tests of Patients Treated With Dynamic Cancer ARCtherapy for Bronchopulmonary Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      assess the consequences of low doses of radiation delivered by the volumetric radiotherapy,&#xD;
      on the respiratory capacity of patients treated for bronchopulmonary carcinoma, by a follow&#xD;
      up of functional respiratory exploration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation therapy with or without chemotherapy is a stable treatment in the management of&#xD;
      patients with localized smack cell bronchopulmonary cancers, or not to small cells not&#xD;
      metastatic but not operable. Radiation therapy results in changes in respiratory function, as&#xD;
      measured by respiratory function tests and represented primarily by spirometry, total body&#xD;
      plethysmography, and the diffusion capacity of the alveolar-capillary membrane.&#xD;
&#xD;
      Although these tests are minimally invasive, few studies have investigated the implications&#xD;
      of radiation therapy on lung function in patients treated for pulmonary neoplasia, while&#xD;
      these patients are often already carriers of respiratory diseases and will receive further&#xD;
      chemotherapy during their illness, subject to their general good condition, including&#xD;
      respiratory. No method has been recognized as superior for measuring the consequences of&#xD;
      radiation therapy on respiratory function. After chest radiotherapy alone, the decline in&#xD;
      diffusion capacity is estimated at 10-34%. New irradiation techniques have emerged over the&#xD;
      last decade, in particular dynamic arc therapy. This innovative technology, combined with&#xD;
      image-guided irradiation processes, ensures high-precision, short-term treatment, but exposes&#xD;
      virtually all of the lungs to irradiation, although at very low doses, the objective&#xD;
      consequences of which on respiratory functional explorations have never been reported.&#xD;
&#xD;
      The aim of this study is therefore to assess the consequences of low doses of radiation&#xD;
      delivered by this recent technology, volumetric therapy, on the respiratory capacity of&#xD;
      patients treated with radiotherapy within the framework of of bronchopulmonary carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">January 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>diffusion capacity</measure>
    <time_frame>3 months</time_frame>
    <description>diminution of 20% or more of the diffusion capacity at 3 months</description>
  </primary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Cancer, Lung</condition>
  <condition>Radiotherapy; Complications</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary function tests</intervention_name>
    <description>analysis of lung volume and diffusion capacity</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with bronchopulmonary carcinoma treated by radio(chimio)therapy alone&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;18 years&#xD;
&#xD;
          -  bronchopulmonary carcinoma histological proved&#xD;
&#xD;
          -  OMS 0-2&#xD;
&#xD;
          -  indication of radio(chimio)therapy alone approved by multidisciplinary comitee&#xD;
&#xD;
          -  non opposition formular completed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  SBRT indication&#xD;
&#xD;
          -  history of thoracic surgery or irradiation&#xD;
&#xD;
          -  unstable disease&#xD;
&#xD;
          -  oxygenotherapy dependance&#xD;
&#xD;
          -  severe chronic bronchitis&#xD;
&#xD;
          -  collagen disease&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  contraception refusal&#xD;
&#xD;
          -  refusal or incapacity to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ulrike SHICK</last_name>
    <phone>02 98 22 33 98</phone>
    <email>ulrike.schick@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Brest (Morvan)</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike SCHICK</last_name>
      <phone>02 98 22 33 98</phone>
      <email>ulrike.schick@chu-brest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after the publication of result and ending three years maximum following the last visit of the last patient</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. requestors will be required to sign and complete a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

